Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 13/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CCR7 | P32248 | 2/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951413 | 0.93 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2CXCR2KDM4E | |
| SCHEMBL2899683 | 0.90 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2CXCR2CCR7 | |
| SCHEMBL490008 | 0.90 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2CXCR2CCR7 | |
| SCHEMBL3754582 | 0.87 | CXCR2 (0.45) | RAB9ANPC1SMN1; SMN2CXCR2KDM4E | |
| SCHEMBL3852995 | 0.84 | CXCR2 (0.49) | CXCR2CCR7CXCR1 | |
| Dimethylamine SCHEMBL3755681 | 0.84 | CXCR2 (0.46) | RAB9ANPC1CXCR2CCR7CXCR1 | |
| SCHEMBL490245 | 0.81 | CXCR2 (0.50) | CXCR2CCR7 | |
| SCHEMBL490032 | 0.81 | CXCR2 (0.47) | CXCR2CCR7MEN1KMT2A | |
| SCHEMBL490193 | 0.81 | CXCR2 (0.73) | CXCR2CCR7 | |
| SCHEMBL28010834 | 0.80 | KMT2A (0.54) | CXCR2CCR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579342-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1419158-B1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-6958344-B2 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-10-20 | — | — | US | disclosed |
| US-6949643-B2 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1385854-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1385854-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003024966-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1265899-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002083693-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001058902-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | CCR5, CXCR3, CCR2 | RAB9A 1135/4885NPC1 1970/4885SMN1; SMN2 4550/4885 |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CCR5, CXCR1, CXCR4 | RAB9A 2666/4885NPC1 1708/4885SMN1; SMN2 4674/4885 |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR2 | RAB9A 2676/4885NPC1 1898/4885SMN1; SMN2 4685/4885 |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | RAB9A 2098/4885NPC1 2420/4885SMN1; SMN2 4855/4885 |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | RAB9A 1135/4885NPC1 1970/4885SMN1; SMN2 4550/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | RAB9A 2098/4885NPC1 2420/4885SMN1; SMN2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.